<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52420/2071-5943-2021-20-2-106-110</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-785</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Опыт успешного применения экстракорпоральных методов лечения синдрома лизиса опухоли</article-title><trans-title-group xml:lang="en"><trans-title>Experience in the successful application of extracorporeal methods in treatment of tumor lysis syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ворошин</surname><given-names>Д. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Voroshin</surname><given-names>D. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ворошин Дмитрий Геннадьевич, к.м.н.</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Dmitrij G. Voroshin, PhD</p><p>Chelyabinsk</p></bio><email xlink:type="simple">d.voroshin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белобородов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Beloborodov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белобородов Владислав Вячеславович</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Vladislav V. Beloborodov</p><p>Chelyabinsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7807-8479</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Важенин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vazhenin</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Важенин Андрей Владимирович</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Andrey V. Vazhenin</p><p>Chelyabinsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермаков</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ermakov</surname><given-names>М. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ермаков Михаил Анатольевич, к.м.н.</p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Mihail A. Ermakov, PhD</p><p>Chelyabinsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»; ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России;  ГБУЗ «Челябинская областная клиническая больница №3»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University;  Chelyabinsk Regional Clinical Hospital No. 3</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2021</year></pub-date><volume>20</volume><issue>2</issue><fpage>106</fpage><lpage>110</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ворошин Д.Г., Белобородов В.В., Важенин А.В., Ермаков М.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ворошин Д.Г., Белобородов В.В., Важенин А.В., Ермаков М.А.</copyright-holder><copyright-holder xml:lang="en">Voroshin D.G., Beloborodov V.V., Vazhenin А.V., Ermakov М.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/785">https://www.umjusmu.ru/jour/article/view/785</self-uri><abstract><sec><title>Введение</title><p>Введение. В данной статье на примере клинического случая отражена проблема развития синдрома лизиса опухоли (СЛО). Чаще всего причиной развития СЛО является противоопухолевое лечение: лучевая терапия, радиочастотная абляция, эмболизация сосудов, применение моноклональных антител, высокодозная химиотерапия с трансплантацией СТК из периферической крови. Данное нарушение приводит к развитию метаболических, гемодинамических, респираторных и ренальных нарушений СЛО, отличает высокие показатели летальности — от 17% до 70%.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Представлено клиническое наблюдение успешного лечения пациентки 30 лет, СЛО III степени клинического течения по Каиро-Бишопу с применением заместительной почечной терапии на аппарате Prismaflex в условиях палаты реанимации и интенсивной терапии ГБУЗ «ЧОКЦО и ЯМ».</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. При обращении пациентки в ГБУЗ «ЧОКЦО и ЯМ» установлен диагноз «Неходжскинская лимфома с диффузным типом роста высокой степени злокачественности». Выявлено поражение лимфатических узлов, париетальной плевры, правого гемиторакса, ателектаз средней доли правого легкого с воздушной бронхографией, гидроторакс с обеих сторон, гидроперикард, свободная жидкость в полости малого таза, флеболиты параметральной клетчатки, дегенеративно-дистрофические изменения позвоночника. В первые сутки госпитализации начата антибактериальная, противоболевая терапия, коррекция нутритивных нарушений. После проведения предфазы химиотерапии (циклофосфан, винкристин) отмечено ухудшение состояния пациентки, переведена в отделение реанимации, где было проведено лечение судорожного синдрома, дыхательной недостаточности, острой почечной недостаточности, двусторонней пневмонии, ТЭЛА. На фоне данной терапии продолжено специальное лечение — 2 цикла химиотерапии. После перехода на самостоятельное дыхание и нормализации показателей шлаков крови и калия пациентка была переведена в отделение противоопухолевой терапии для продолжения специального лечения.</p></sec><sec><title>Заключение</title><p>Заключение. Выполненный алгоритм лечения СЛО привел к положительной динамике и возможности проведения специальной противоопухолевой терапии пациентки.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. This article, using a clinical case as an example, reflects the problem of the development of tumor lysis syndrome (TLS). The most common cause of SLO development is antitumor treatment: radiation therapy, radiofrequency ablation, vascular embolization, the use of monoclonal antibodies, high-dose chemotherapy with transplantation of stasis from peripheral blood. This disorder leads to the development of metabolic, hemodynamic, respiratory and renal disorders. The TLS distinguished by high mortality rates, from 17% to 70%.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Presented a clinical case of patient, 30 years old - observation of successful treatment of TLS of the III degree of clinical course according to Cairo-Bishop, in the conditions of the State Budgetary Healthcare Institution «Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine», in the conditions of the intensive care unit and intensive care with the use of renal replacement therapy on the Prismaflex device.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. When the patient applied to the State Budgetary Healthcare Institution «Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine», the diagnosis made — Non-Hodgkin lymphoma with a diffuse type of growth of a high degree of malignancy. Revealed the defeat of the lymph nodes, parietal pleura, right hemithorax, atelectasis of the middle lobe of the right lung with air bronchography, hydrothorax on both sides, hydropericardium, free fluid in the pelvic cavity, phlebolitis of the parametric tissue, degenerative-dystrophic changes in the spine. On the first day of hospitalization, antibacterial and pain relief therapy started, and nutritional disturbances were corrected. After the pre-phase chemotherapy (cyclophosphamide, vincristine), the patient's condition worsened, she was transferred to the intensive care unit. Where was the treatment carried out: convulsive syndrome, respiratory failure, acute renal failure, bilateral pneumonia, PE. Against the background of this therapy, special treatment continued - 2 cycles of chemotherapy. After the patient transferred to spontaneous breathing and the indices of blood slags and potassium were normalized, she was transferred to the antitumor therapy department to continue special treatment.</p></sec><sec><title>Conclusion</title><p> Conclusion. Our algorithm for the treatment of SLO led to positive dynamics and the possibility of carrying out special antitumor therapy for this patient. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром лизиса опухоли</kwd><kwd>экстракорпоральные методы лечения</kwd><kwd>противоопухолевая лекарственная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tumor lysis syndrome</kwd><kwd>extracorporeal treatment methods</kwd><kwd>antitumor drug therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Berghe, G. Purine and pyrimidine metabolism between millennia: what has been accomplished, what has to be done? // Adv Exp Med Biol. – 2000. – Vol. 486. – Р. 1–4.</mixed-citation><mixed-citation xml:lang="en">Van den Berghe, G. Purine and pyrimidine metabolism between millennia: what has been accomplished, what has to be done? // Adv Exp Med Biol. – 2000. – Vol. 486. – Р. 1–4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yeung, S. C. Metabolic and endocrine emergencies. / Yeung S. C., Lazo-Diaz G., Gagel R. F. // Oncologic emergencies. Hamilton, BC Decker. – 2002. – P. 103-44.</mixed-citation><mixed-citation xml:lang="en">Yeung, S. C. Metabolic and endocrine emergencies. / Yeung S. C., Lazo-Diaz G., Gagel R. F. // Oncologic emergencies. Hamilton, BC Decker. – 2002. – P. 103-44.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Arrambide, K. Tumor lysis syndrome / K. Arrambide, R. D. Toto // Semin Nephrol. –1993. – Vol. 13. – Р. 273-80.</mixed-citation><mixed-citation xml:lang="en">Arrambide, K. Tumor lysis syndrome / K. Arrambide, R. D. Toto // Semin Nephrol. –1993. – Vol. 13. – Р. 273-80.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Flombaum, C. D. Metabolic emergencies in the cancer patient // Semin Nephrol. – 2000. – Vol. 27. – Р. 322-34.</mixed-citation><mixed-citation xml:lang="en">Flombaum, C. D. Metabolic emergencies in the cancer patient // Semin Nephrol. – 2000. – Vol. 27. – Р. 322-34.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jones, D. P. Tumor lysis syndrome / D. P. Jones, H. Mahmoud, R. W. Chesney // Pediatr Nephrol. – 1995. – Vol. 9. – Р. 206-12.</mixed-citation><mixed-citation xml:lang="en">Jones, D. P. Tumor lysis syndrome / D. P. Jones, H. Mahmoud, R. W. Chesney // Pediatr Nephrol. – 1995. – Vol. 9. – Р. 206-12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сравнительный анализ причин смертности в детских онкогематологических центрах Австрии и России / Румянцев С. А., Позднякова О. О., Цубек А. [и др.] // Мат. конференции «Актуальные вопросы гематологии и трансфузиологии». – С.-Пб., 1996. – С. 128.</mixed-citation><mixed-citation xml:lang="en">Сравнительный анализ причин смертности в детских онкогематологических центрах Австрии и России / Румянцев С. А., Позднякова О. О., Цубек А. [и др.] // Мат. конференции «Актуальные вопросы гематологии и трансфузиологии». – С.-Пб., 1996. – С. 128.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu, H. H. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach / H. H.Hsu, Y. L. Chan, C. C. Huanq // J Nephrol. – 2004. – Vol. 17 (1). – Р. 50-6.</mixed-citation><mixed-citation xml:lang="en">Hsu, H. H. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach / H. H.Hsu, Y. L. Chan, C. C. Huanq // J Nephrol. – 2004. – Vol. 17 (1). – Р. 50-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tumor lysis syndrome following hemibody irradiation for metastatic breast cancer / A. Y. Rostom, G. El-Hussainy, A. Kandyl, A. Allam // Ann Oncol. – 2000. – Vol. 11 (10). – Р. 1349-51.</mixed-citation><mixed-citation xml:lang="en">Tumor lysis syndrome following hemibody irradiation for metastatic breast cancer / A. Y. Rostom, G. El-Hussainy, A. Kandyl, A. Allam // Ann Oncol. – 2000. – Vol. 11 (10). – Р. 1349-51.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffer, N. Severe tumor lysis syndrome following splenic irradiation / N. Schiffer, A. Cohen, U. H. Lewinski // Am J Hematol. – 1999. – Vol. 60. – Р. 75-6.</mixed-citation><mixed-citation xml:lang="en">Schiffer, N. Severe tumor lysis syndrome following splenic irradiation / N. Schiffer, A. Cohen, U. H. Lewinski // Am J Hematol. – 1999. – Vol. 60. – Р. 75-6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia / Vassban E., Zaina A., Braester A. [et al.] // Ann Hematol. – 2001. – Vol. 80 (5). – Р. 314-5.</mixed-citation><mixed-citation xml:lang="en">Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia / Vassban E., Zaina A., Braester A. [et al.] // Ann Hematol. – 2001. – Vol. 80 (5). – Р. 314-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Acute tumour lysis syndrome following a singledose corticosteroid in children with acute lymphoblastic leukaemia / A.Duzova, M. Cetin, F. Gümrük, S. Yetqin // Eur J Hematol. – 2001. – Vol. 66 (6). – 404-7.</mixed-citation><mixed-citation xml:lang="en">Acute tumour lysis syndrome following a singledose corticosteroid in children with acute lymphoblastic leukaemia / A.Duzova, M. Cetin, F. Gümrük, S. Yetqin // Eur J Hematol. – 2001. – Vol. 66 (6). – 404-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Acute tumor lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone / O. J. Loosveld, H. C. Schouten, C. A. Gaillard, G. H. Bligham // Br J Haematol. – 1991. – Vol. 77. – Р. 122-3.</mixed-citation><mixed-citation xml:lang="en">Acute tumor lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone / O. J. Loosveld, H. C. Schouten, C. A. Gaillard, G. H. Bligham // Br J Haematol. – 1991. – Vol. 77. – Р. 122-3.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Barry B. D. lysis syndrome following endoscopic radiofrequency interstitial thermal ablation of colorectal liver metastases / B. D. Barry, M. R. Kell, H. P. Redmond // Surg Endosc. – 2002. – Vol. 16 (7). – Р. 1109.</mixed-citation><mixed-citation xml:lang="en">Barry B. D. lysis syndrome following endoscopic radiofrequency interstitial thermal ablation of colorectal liver metastases / B. D. Barry, M. R. Kell, H. P. Redmond // Surg Endosc. – 2002. – Vol. 16 (7). – Р. 1109.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma / S. G. Lehner, J. E. Gould, W. E. Saad, D. B. Brown // AJR Am J Roentgenol. – 2005. – Vol. 185 (5). – Р. 1307-9.</mixed-citation><mixed-citation xml:lang="en">Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma / S. G. Lehner, J. E. Gould, W. E. Saad, D. B. Brown // AJR Am J Roentgenol. – 2005. – Vol. 185 (5). – Р. 1307-9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Barry, B. D. Tumor lysis syndrome following endoscopic radiofrequency interstitial thermal ablation of colorectal liver metastases / B. D. Barry, M. R. Kell, H. P. Redmond // Surg Endosc. – 2002. – Vol. 16 (7). – Р. 1109.</mixed-citation><mixed-citation xml:lang="en">Barry, B. D. Tumor lysis syndrome following endoscopic radiofrequency interstitial thermal ablation of colorectal liver metastases / B. D. Barry, M. R. Kell, H. P. Redmond // Surg Endosc. – 2002. – Vol. 16 (7). – Р. 1109.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gersosimo, R. J. Monoclonal antibodies in the treatment of cancer. Part 2. // Am J Health Syst. – 2003. – Vol. 60 (16). – Р. 1631-41.</mixed-citation><mixed-citation xml:lang="en">Gersosimo, R. J. Monoclonal antibodies in the treatment of cancer. Part 2. // Am J Health Syst. – 2003. – Vol. 60 (16). – Р. 1631-41.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon / Fer M. F., Bottino G. C., Scerwin S. A. [et al.] // Am J Med. – 1984. – Vol. 77 (5). – Р. 953-6.</mixed-citation><mixed-citation xml:lang="en">Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon / Fer M. F., Bottino G. C., Scerwin S. A. [et al.] // Am J Med. – 1984. – Vol. 77 (5). – Р. 953-6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature / Castro M. P., Van Auken J., Spencer-Cisek P. [et al.] // Cancer. – 1999. – Vol. 85 (5). – 1055-9.</mixed-citation><mixed-citation xml:lang="en">Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature / Castro M. P., Van Auken J., Spencer-Cisek P. [et al.] // Cancer. – 1999. – Vol. 85 (5). – 1055-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature / Castro M. P., Van Auken J., Spencer-Cisek P. [et al.] // Cancer. – 1999. – Vol. 85 (5). – Р. 1055-9.</mixed-citation><mixed-citation xml:lang="en">Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature / Castro M. P., Van Auken J., Spencer-Cisek P. [et al.] // Cancer. – 1999. – Vol. 85 (5). – Р. 1055-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cairo, M. S. Tumour lysis syndrome: New therapeutic strategies and classification / M. S. Cairo, M. Bishop // Br J Haematol. – 2004. – Vol. 127. – Р. 3–11.</mixed-citation><mixed-citation xml:lang="en">Cairo, M. S. Tumour lysis syndrome: New therapeutic strategies and classification / M. S. Cairo, M. Bishop // Br J Haematol. – 2004. – Vol. 127. – Р. 3–11.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Громова, Е. Г.Синдром лизиса опухоли: патогенез, клиника, профилактика, лечение / Е. Г. Громова, Л. С. Кузнецова // Онкогематология. – 2007. – № 3. – С. 61–64.</mixed-citation><mixed-citation xml:lang="en">Громова, Е. Г.Синдром лизиса опухоли: патогенез, клиника, профилактика, лечение / Е. Г. Громова, Л. С. Кузнецова // Онкогематология. – 2007. – № 3. – С. 61–64.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sarno, J. Prevention and Management of Tumor Lysis Syndrome in Adults With Malignancy / J Adv Pract Oncol. – 2013. – Vol. 4 (2). – Р. 101-106.</mixed-citation><mixed-citation xml:lang="en">Sarno, J. Prevention and Management of Tumor Lysis Syndrome in Adults With Malignancy / J Adv Pract Oncol. – 2013. – Vol. 4 (2). – Р. 101-106.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Синдром лизиса опухоли: взгляд на проблему / Харченко Ю. А., Нагорный И. П., Дмитриев В. Н., [и др.] // Онко-</mixed-citation><mixed-citation xml:lang="en">Синдром лизиса опухоли: взгляд на проблему / Харченко Ю. А., Нагорный И. П., Дмитриев В. Н., [и др.] // Онко-</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
